This is a "connection" page, showing publications co-authored by Elizabeth Hill and Andrew Kraft.
Connection Strength

  1. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
    View in: PubMed
    Score: 0.202
  2. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28; 115(4):824-33.
    View in: PubMed
    Score: 0.094
  3. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049.
    View in: PubMed
    Score: 0.044
  4. PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest. 2018 07 02; 128(7):2787-2801.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.